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ABSTRACT
The somatostatin analog octreotide can lead to hyperbilirubine-
mia without evidence of liver injury. Here we investigate whether
octreotide inhibits the main sinusoidal/canalicular bilirubin
carriers and whether it is a transport substrate. Octreotide
showed the most potent inhibitory effect toward OATP1B1-
mediated transport and weaker inhibition for OATP1B3- and
MRP2-mediated transport. Octreotide had no effect on
OATP2B1-mediated transport. Octreotide inhibited [3H]estradiol-
17-b-glucuronide (E17bG) influx mediated by OATP1B1, 1B3,
and multidrug resistance-associated protein 2 (MRP2) in
a concentration-dependent manner, and the IC50 values
were computed to be 23 mM (95% confidence interval [CI]
18-29), 68 mM (95% CI 50-91), and 116.6 mM (95% CI
74.5–182.4), respectively. The interaction between octreotide
and OATP1B1 was further studied. Inhibition of [3H]E17bG
OATP1B1-mediated transport was purely competitive with no
changes in maximum transport capacity (Vmax) and a twofold
Km increase when the influx kinetics of [
3H]E17bG were
measured in the presence of octreotide (8.8 6 3.1 versus 4.4 6
1.2 mM, P 5 0.03). The inhibition constant (Ki) of octreotide
for the transport of [3H]E17bG was calculated at 33.5 6 5.5 mM.
Uptake of radiolabeled octreotide by OATP1B1-CHO cells
was higher than in wild-type CHO cells and nonlabeled octreo-
tide at the extracellular compartment was able to trans-
stimulate the OATP1B1-mediated efflux of intracellular
[3H]E17bG, suggesting that octreotide is a substrate of
OATP1B1. In summary, this study shows interaction of
octreotide on the human hepatocellular bilirubin transporters
OATP1B1, OATP1B3, and MRP2, notably OATP1B1. These
findings are in line with the clinical observation that a frac-
tion of patients under treatment with octreotide exhibit
hyperbilirubinemia.
Introduction
Somatostatin is an endogenous inhibitory peptide (14 amino
acids) that modulates neurogastroenterological motility at
various levels. By binding specific membrane receptors,
somatostatin inhibits the secretion of neurotransmitters,
growth hormone, thyroid-stimulating hormone, pancreatic
enzymes, and neuropeptides (Theodoropoulou and Stalla,
2013).
Because of its broad and potent antisecretory effect,
somatostatin would have many pharmacological applica-
tions; however, its short half-life (∼3 minutes) and the
requirement for intravenous administration make it diffi-
cult to use in clinical practice (Patel and Wheatley, 1983;
Lamberts et al., 1996). The recognized therapeutic benefits of
somatostatin led to the development of somatostatin analogs
with an improved pharmacological profile. The first to be
introduced for clinical use was octreotide, a cyclic octapeptide
with a longer half-life (∼2 hours) and greater inhibitory effect
compared with that of the endogenous somatostatin. Octreo-
tide is used in the treatment of many hyperfunctional
organ conditions such as acromegaly, thyroid-stimulating
hormone-secreting pituitary adenomas, and neuroendo-
crine tumors (Lamberts et al., 1996; Theodoropoulou and
Stalla, 2013). Octreotide is also employed as a radioligand
for the imaging and treatment of somatostatin receptor-
expressing tumors (i.e., neuroendocrine tumors) (Toumpa-
nakis and Caplin, 2013). Octreotide is mainly cleared into
bile in unchanged form (Berelowitz et al., 1978; Bauer et al.,
1982; Lemaire et al., 1989) and can lead to hyperbilirubi-
nemia and asymptomatic gallbladder stone formation,
albeit without signs of liver injury (Arosio et al., 1988;
Hussaini et al., 1994; Radetti et al., 2000; Crook and Steger,
2001; Pereira et al., 2001; Koren et al., 2013). Nevertheless,
the mechanism of the vectorial transport of octreotide from
portal blood into bile has been only partially studied with
conflicting results and none has investigated the interac-
tion of octreotide with the main human liver transporters
(Terasaki et al., 1995; Yamada et al., 1996, 1997; Gutmann
et al., 2000).
This work was supported by the Swiss National Science Foundation [Grant
320030_144193 / 1].
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ABBREVIATIONS: ASP1, 4-(4-(dimethylamino)-styryl)-N-methylpyridinium iodide; BSP, sulphobromophtalein; CI, confidence interval; E17bG,
estradiol-17-b-glucoronide; EHBR, Eisai hyperbilirubinemic rats; E3S, estrone-3-sulfate; ICG, indocyanine green; NS, not significant; NTCP,
Na1-taurocholate cotransporting polypeptide; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; WT, wild-type.
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The objective of the current study was a comprehensive
analysis of the potential role of the main sinusoidal/canalicular
transport systems in the clearance of octreotide byusing in vitro
models that selectively expressed the different human hepatic
membrane transporters.
Methods
Reagents. [6,7-3H(N)]estrone-3-sulfate ([3H]E3S, 45.6 Ci/mmol),
[6,7-3H(N)]estradiol-17-b-glucuronide (E17bG, 45 Ci/mmol), [3H(G)]
taurocholic acid (5.0 Ci/mmol) were purchased from PerkinElmer
(Boston,MA). The generally labeled [3H]octreotide was synthesized by
Moravek Biochemicals (Brea, CA). Nonlabeled octreotide was pur-
chased from Abbiotec (San Diego, CA). Nonlabeled E3S, taurocholic
acid sodium salt, E17bG, indocyanine green (ICG), and sulphobro-
mophtalein (BSP) were provided from Sigma-Aldrich (St. Louis, MO)
and 4-[4-(dimethylamino)-styryl)-N-methylpyridinium iodide] (ASP1)
by Molecular Probes/Life Technologies (Carlsbad, CA).
Cell Lines. Wild-type (WT) CHO and HEK293 cells were main-
tained inDulbecco’smodifiedEagle’smedium supplementedwith 10%
fetal bovine serum (Gibco, Paisley, UK), 100 units/ml penicillin, and
100 mg/ml streptomycin at 37°C in a humidified atmosphere with 5%
CO2. Wild-type CHO were further supplemented with 0.05 mg/ml
L-proline.
OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and OATP2B1
(SLCO2B1) stably transfected CHO cells (Treiber et al., 2007; Gui
et al., 2008) were grown under selective pressure with Geneticin
G-418 (500 mg/ml) (Gibco). CHO FlpIn cells stably expressing the
Na1-taurocholate cotransporting polypeptide (NTCP-SLC10A1) were
grown in Ham’s F-12 medium containing 10% fetal bovine serum,
100 units/ml penicillin, 100 mg/ml streptomycin, 1 mM L-glutamine,
and 500 mg/ml hygromycin B as selecting agent (deWaart et al., 2010).
HEK293 cells stably transfected with the human organic cation
transporter (OCT1-SLC22A1), kindly provided by Dr. Hermann
Koepsell, Würzburg, Germany, were supplemented with Geneticin
G-418 (600 mg/ml) (Thevenod et al., 2013).
Sf21 insect cells were grown in a humidified atmosphere at 27°C on
10-cm Petri dishes in BD BaculoGold TNM-FH insect medium (BD
Bioscience, Allschwil, Switzerland) supplemented with 100 units/ml
penicillin and 100 mg/ml streptomycin.
MRP2 Expression in Insect Cells. Sf21 cells were infected with
baculovirus human MRP2 [multidrug resistance-associated protein 2
(MRP2); ATP-binding cassette C2] (de Waart et al., 2006; Guyot et al.,
2014). The isolation of membrane vesicles from infected cells was
performed as previously described (Gerloff et al., 1998). The vesicles
were resuspended in 50 mM sucrose, 100 mM KNO3, 20 mM Hepes/
Tris pH 7.4, and loaded with 1 mM cholesterol for optimal MRP2
transport activity (Guyot et al., 2014); a portion was used for protein
determination by the bicinchoninic acid assay (Interchim, Montluçon
Cedex, France), and the remaining part was used for the transport
assay.
Transport Studies in Intact Cells. Initial uptake of tritiated or
fluorescent compounds was measured using a protocol designed for
rapid uptake determination in cells (Schroeder et al., 1998). Cells
were seeded in 35-mm dishes at a density of 2.5  105 cells/dish and
grown for 3 days in regular medium. For the seeding of WT-HEK293
and OCT1-HEK293 cells, 35-mm dishes were coated with 0.1 mg/ml
poly-D-lysine (Sigma-Aldrich). Twenty-four hours before the uptake
measurement, cells were treated with 5 mM sodium butyrate (Sigma-
Aldrich) to induce gene expression (Kim and Lee, 2000–2001). Medium
was aspirated and cells were rinsed twice with prewarmed transport
buffer (116.4 mMNaCl, 5.3 mMKCl, 1 mMNaH2PO4, 0.8 mMMgSO4,
5.5 mM D-glucose, and 20 mMHepes/Tris, pH 7.4). When the transport
of [3H]octreotide was measured, 20 mM MgCl2 was added to the
transport buffer to reduce the nonspecific background signal, attribut-
able presumably to the electrostatic binding of octreotide to cell
membranes (Beschiaschvili and Seelig, 1991; Ben-Tal et al., 1997).
The transport experiments in HEK293 cells were performed in
a transport buffer containing 136 mM NaCl, 5.3 mM KCl, 1.1 mM
KH2PO4, 1.8mMCaCl2, 0.8mMMgSO4, 11mMD-glucose, and 10mM
Hepes/Tris, pH 7.4.
Cells were equilibrated in transport buffer at 37°C, and then the
buffer was aspirated and transport buffer containing the labeled
reagents was added. Uptake was stopped by quick aspiration of the
labeled cocktail followed by extensive washing with ice-cold transport
buffer. Cells were digested with 1 ml of 1% (v/v) Triton X-100. Lysate
(500 ml) was mixed with 10 ml of Scintillation Liquid (Ultima Gold,
PerkinElmer) and assessed for intracellular radioactivity by liquid
scintillation counting. To measure the intracellular ASP1, the
fluorescence (lex 5 485 nm, lem 5 590 nm) of a 150-ml aliquot was
measured on the Twinkle LB970 microplate fluorometer (Berthold
Technologies, Bad Wildbad, Germany). Protein content was deter-
mined by the bicinchoninic acid protein assay on a 25-ml aliquot. In
OATP/OCT1 transport experiments, OATP/OCT1-independent up-
takewas determined inWT-CHO andWT-HEK293 cells, respectively,
and subtracted from total uptake to quantify OATP- and OCT1-
mediated uptake.
When NTCP-mediated transport was measured, nonspecific trans-
port was assayed in a Na1-free buffer that maintained osmolarity by
replacement of Na1 with choline (116.4 mM choline chloride, 5.3 mM
KCl, 1 mM KH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose, and 20 mM
Hepes/Tris, pH 7.4) (de Waart et al., 2010). Influx is expressed as
picomoles of substrate per milligram of protein per minute.
For efflux studies, cells were incubated with 10 mM [3H]E17bG for
30 minutes at pH 7.4, washed extensively in ice-cold drug-free buffer,
and suspended into a large volume of prewarmed transport buffer at
pH 7.4. At different time points, portions were injected into 0°C
transport buffer andwashed twice, and protein and radioactivity were
analyzed as indicated above.
Membrane Vesicle Transport Studies. ATP-dependent uptake
by MRP2 was measured using the rapid filtration technique as
previously described (Gerloff et al., 1998). Briefly, vesicles were
extracted and resuspended to a final concentration of 3.5 mg/ml in
50 mM sucrose, 100 mM KNO3, 10 mM Hepes, adjusted with Tris to
pH 7.4; 70 mg of vesicles were preincubated in a 37°C water bath, and
uptakewas initiated by injecting the radiolabeled compound dissolved
in the uptake buffer (50 mM sucrose, 100 mM KNO3, 12.5 mM Mg
(NO3)2, 5 mM ATP, 10 mM Hepes/Tris, pH 7.4). Uptake was also
measured in the absence of ATP, and ATP-dependent uptake was
calculated as the difference in uptake in the presence and in the
absence of ATP. Transport was stopped by adding 3 ml of ice-cold stop
solution (50 mM sucrose, 100 mM KCl, 10 mM Tris/HCl, pH 7.4)
followed by filtration through 0.45-mm nitrocellulose acetate filter
(Sartorius, Göttingen,Germany). Afterward, the filterwas extensively
washed, dissolved in 3 ml of liquid scintillation fluid (Filter Count;
PerkinElmer), and radioactivity was measured on a liquid scintillation
counter. Influx is expressed as picomoles of substrate per milligram of
protein per minute.
Statistical Analysis. Statistical comparisons were performed
from three independent measurements, at least, with the two-tailed
Student’s t test using GraphPad Prism (version 5.0 for Windows,
GraphPad Software, La Jolla, CA). The IC50 values were computed
from a log (inhibitor) versus response curve derived from the formula:
Y 5 100/[1110(X2LogIC50
)], where X is the logarithm of the concentra-
tion of the inhibitor and Y is the response expressed as percentage of
the control (no inhibitor).
Results
Effect of Octreotide on OCT1-Mediated Transport.
OCT1 is the main cation transporter expressed at the baso-
lateral membrane of hepatocytes. To determine whether
octreotide (z 5 12) interacts with this carrier, OCT1-
HEK293 cells were coincubated for 2 minutes (linear range)
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with 2 mM fluorescent substrate ASP1 and increasing concen-
trations of octreotide (Schlatter et al., 2002). Figure 1 illustrates
that intracellular ASP1 decreased as the extracellular concen-
tration of octreotide increased. The IC50 was computed to be
93.7 6 1.1 mM [95% confidence interval (CI) 71.0–123.5].
Impact of Octreotide on the Transport Mediated by
OATP1B1, 1B3, and 2B1. To assess the potential interac-
tion of octreotide with OATP1B1 and 1B3, the influx of 1 mM
[3H]E17bG was assessed as a function of the extracellular
concentration of nonlabeled octreotide. Because [3H]E17bG is
not a substrate of OATP2B1 (Tamai et al., 2001), 1 mM [3H]E3S
was used to determine the effect of nonlabeled octreotide on
transport mediated by OATP2B1. Transport was performed
over 1 minute, because over this time period uptake was
unidirectional (unpublished data). The influx of [3H]E17bG
mediated by OATP1B1 (Fig. 2A) or OATP1B3 (Fig. 2B) was
inhibited by nonlabeled octreotide in a concentration-
dependent manner, and the IC50 values were computed to be
24.16 1.1 mM (95% CI 19.2–30.4) and 72.761.2 mM (95% CI
47.9–110.4), respectively. Figure 2C shows that extracellular
octreotide had no effect on the influx of [3H]E3S mediated by
OATP2B1. In the presence of 200 mM extracellular octreotide
the influx of 1 mM [3H]E3S was comparable to that in the
octreotide-free buffer [11.0 6 4.5 versus 10.6 6 4.3 pmol/mg of
protein/min, P5 not significant (NS)]. As expected, ICG (5 mM)
or BSP (5 mM), two potent inhibitors of OATP2B1-mediated
transport (Kullak-Ublick et al., 2001; de Graaf et al., 2011),
markedly reduced [3H]E3S influx, by ∼97% (0.3 6 1.4 versus
10.66 4.3 pmol/mg of protein/min,P5 0.02) and 75% (2.66 0.6
versus 10.6 6 4.3 pmol/mg of protein/min, P 5 0.03), re-
spectively, compared with uptake in the absence of inhibitors.
Impact of Octreotide on Na1-Dependent Bile Salt
Transport. In rat hepatocytes, octreotide has been suggested
to be transported by the Na1-dependent bile salt carrier
(Terasaki et al., 1995). To investigate whether the human
Na1-taurocholate cotransporting polypeptide (NTCP) was
inhibited by octreotide, the influx of 0.5 mM [3H]taurocholic
acid was assessed in NTCP-CHO cells after coincubation with
nonlabeled octreotide. As a control, the influx of [3H]taur-
ocholic acid was also measured in the presence of ICG or BSP,
known inhibitors of NTCP-mediated transport (Hagenbuch
and Meier, 1994; de Graaf et al., 2011). Figure 3 shows that
extracellular ICG (10 mM) or BSP (200 mM)markedly reduced
[3H]taurocholic acid influx by ∼65 and 95%, respectively,
compared with uptake in the absence of inhibitors. When the
influx of [3H]taurocholic acid was measured in the presence of
200 mM octreotide in the extracellular compartment, there was
no difference in the amount of intracellular [3H]taurocholic acid
compared with that in the absence of octreotide (10.5 versus
11.2 pmol/mg of protein/min, P 5 NS).
Impact of Octreotide on the Transport of [3H]E17bG
Mediated by MRP2. Organic anion transporting polypep-
tides (OATPs) share a variety of substrates with the canalic-
ular efflux pump MRP2 (Suzuki and Sugiyama, 1999). The
interaction of octreotide with MRP2 was evaluated by mea-
suring the transport of radiolabeled E17bG in Sf21membrane
vesicles. Transport was measured over 90 seconds, because
uptake slopes are linear over this period and extrapolate
Fig. 1. Inhibitory effect of octreotide on OCT1-mediated transport. Influx
of 2 mM fluorescent substrate ASP+ was assessed in OCT1-stably
transfected HEK293 cells at pH 7.4 over 2 minutes in the absence
(control) or presence of nonlabeled octreotide at the indicated concen-
trations. The uptake in wild-type HEK293 cells was subtracted from that
in transfected cells to define the OCT1-specific transport. Data represent
the mean 6 S.D. from three independent experiments and are expressed
as percentage of the control. The IC50 value was computed from a log
(inhibitor) versus response curve.
Fig. 2. Effect of octreotide on OATP-mediated transport. (A and B) Influx
of 1 mM [3H]E17bG was assessed in OATP1B1 and OATP1B3 stably
transfected CHO cells at pH 7.4 over 1 minute in the absence (control) or
presence of nonlabeled octreotide at the indicated concentrations. The
data are expressed as percentage of the control, and the IC50 values were
computed from a log(inhibitor) versus response curve. (C) Influx of 1 mM
[3H]E3S was assessed in OATP2B1-transfected CHO cells at pH 7.4 over
1 minute in the absence (control) or presence of nonlabeled octreotide,
ICG, or BSP at the indicated concentrations. For all the experiments, the
uptake in wild-type CHO cells was subtracted from that in transfected
cells to define the OATP-specific transport. Data represent the mean 6 S.D.
from three independent experiments, at least.
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through the point of origin, indicating unidirectional flux of
[3H]E17bG into vesicles (unpublished data). Figure 4 shows
the influx of [3H]E17bG at an extracellular concentration of
10 mM in the presence of nonlabeled octreotide in the extracel-
lular compartment at the indicated concentrations. Octreotide
inhibited the influx of [3H]E17bG, and the inhibition was concen-
tration dependent. The IC50 was computed to be 116.6 6 1.2 mM
(95% CI 74.5–182.4).
Kinetic Analysis of Inhibition of OATP1B1-Mediated
Transport by Octreotide. To study the nature of the
inhibitory effect of octreotide on [3H]E17bG OATP1B1-
mediated transport, influx kinetics of [3H]E17bG were de-
termined in the presence or absence of extracellular octreotide
in OATP1B1-CHO cells. Influx of [3H]E17bG as a function of
concentration was assessed over 1 minute in the presence or
absence of 60 mM extracellular octreotide and was found to be
saturable (Fig. 5A). Table 1 summarizes the kinetics based
upon the Michaelis-Menten nonlinear regression equation.
The [3H]E17bG influxKm in the presence (Kmapp) or absence of
octreotide was calculated at 8.8 6 3.1 and 4.4 6 1.2 mM,
respectively (P 5 0.03). The dissociation coefficient (Ki) of
octreotide for E17bGwas computed to be 33.56 5.5 mM. Thus,
the maximal transport capacity (Vmax) remained unchanged,
suggesting fully competitive inhibition of [3H]E17bG influx by
nonlabeled octreotide (107.46 8.9 versus 107.06 9.9 pmol/mg
of protein/min, P 5 NS). Figure 5B shows the [3H]E17bG
OATP1B1-mediated influx at two different concentrations of
substrate as the function of extracellular nonlabeled octreo-
tide at the indicated concentrations (Dixon analysis). It can be
seen that the nature of the inhibition was confirmed to be fully
competitive, and theKi value could be estimated to be∼35mM.
Impact of OATP1B1 on [3H]octreotide Transport. To
assess whether octreotide is also a substrate for OATP1B1, the
net uptake of 10mM[3H]octreotidewasmeasured inOATP1B1-
CHO cells. Figure 6 shows that the intracellular accumulation
of [3H]octreotide over 10- and 30-minute incubation periodswas
only slightly higher in OATP1B1-CHO cells compared with
WT-CHO, suggesting a low transport rate even at a substrate
concentration that approached the Ki value. It can be observed
that after 30-minute incubation at the extracellular concentra-
tion of 10 mM, the intracellular [3H]octreotide was only ∼20%
higher inOATP1B1-CHO cells comparedwith that inWT-CHO
cells (259.3 6 32.0 versus 217.1 6 13.5 pmol/mg of protein,
P 5 NS). However, notably there was substantial background
transport/bound level in WT-CHO cells, making further anal-
ysis of the kinetics of OATP1B1 mediated transport difficult.
This was either due to strong membrane binding and/or
nonspecific uptake of [3H]octreotide by an endogenous trans-
port system (Beschiaschvili and Seelig, 1991).
Effect of Extracellular Octreotide on the Efflux of
[3H]E17bG Mediated by OATP1B1. To better understand
whether octreotide was transported by OATP1B1, its ability to
trans-stimulate the OATP1B1-mediated efflux of intracellular
[3H]E17bG was assessed (Eraly, 2008). Cells were incubated
for 30 minutes with 10 mM [3H]E17bG in transport buffer to
achieve high intracellular levels. After an extensive washing at
0°C, the cells were resuspended into a large volume of drug-free
37°C transport buffer and the decline in intracellular
[3H]E17bG was monitored. In parallel, the efflux rate of
[3H]E17bG was monitored in cells resuspended in 37°C trans-
port buffer containing 5 mM BSP (substrate), 5 mM ICG (in-
hibitor), or 100mMoctreotide. At these concentrations based on
the calculated Ki/Kt the carrier molecules in the outward
conformation should approach the saturation. It can be seen
that the OATP1B1-mediated transport was bidirectional and
its cycling rate wasmaximal when the substrate was present at
both sides of the plasmamembrane. In fact, the decline of efflux
of intracellular [3H]E17bG was enhanced by approximately 2-
fold in cells exposed to BSP compared with that in cells
incubated in drug-free transport buffer (20.0050 6 0.0007
versus 20.00876 0.0017 second21, P5 0.04) (Fig. 7A). Unlike
BSP, ICG reduced the efflux rate of intracellular [3H]E17bG by
∼50% (20.0056 6 0.0004 versus 20.0038 6 0.0011 second21,
P 5 0.06) (Fig. 7B). Figure 7C shows that octreotide, like BSP,
was able to enhance the efflux rate of [3H]E17bG (20.0053 6
0.0007 versus 20.0088 6 0.0015 second21, P 5 0.007),
confirming that octreotide was substrate of the OATP1B1.
Discussion
Octreotide, like several other peptides, is rapidly cleared by
the liver, and this process is carrier mediated (Gores et al.,
1989; Ziegler and Seeberger, 1993; Terasaki et al., 1995;
Lamberts et al., 1996). However, it is still unclear which
transporters mediate the vectorial transport of octreotide from
portal blood into bile. This study establishes that octreotide
interacts, to a different extent, with the bilirubin transporters
Fig. 3. Effect of octreotide and other compounds on NTCP-mediated
[3H]taurocholic acid influx. NTCP-CHO cells were incubated for 1 minute
at pH 7.4 with 0.5 mM [3H]taurocholic acid in the presence or absence of
nonlabeled octreotide, ICG, or BSP in the extracellular compartment at
the indicated concentrations. Data were corrected for uptake in Na+-free
buffer. Results are the mean 6 S.D. from three independent experiments.
Fig. 4. Effect of octreotide on MRP2 transport activity. MRP2 expressing
Sf21 vesicles were incubated for 90 seconds at pH 7.4 with 10 mM [3H]
E17bG and in the presence of increasing extravesicular concentrations of
octreotide. Transport was measured either in the presence or absence of
5 mM ATP. The specific MRP2-mediated uptake was the difference
between the uptake values in the presence and absence of ATP. Results
are the mean 6 S.D. from three independent experiments.
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OATP1B1 and OATP1B3 and, at the canalicular domain,
MRP2. Inhibition of this panel of transporters is consistent
with their overlapping substrate specificities (Suzuki and
Sugiyama, 1999). The data are in line with the observation that
patients treated with octreotide can experience hyperbilirubi-
nemia (Arosio et al., 1988; Crook and Steger, 2001; Koren et al.,
2013). Bilirubin is takenup into hepatocytes in part by a carrier-
mediated process involving OATPs 1B1, 1B3, and 2B1 (Kullak-
Ublick et al., 2001; Stieger et al., 2012), is rapidly conjugated to
bilirubin glucuronides by uridine diphosphate-glucuronosyl
transferase (Erlinger et al., 2014), and is then excreted from
hepatocytes into bile canaliculi by the multidrug resistance-
associated protein 2 (MRP2) (Kamisako et al., 1999).
The finding that octreotide, formal charge z512 at pH 7.4,
showed a relatively good affinity (Ki ∼35 mM) for OATP1B1
was not surprising and consistent with the ability of OATPs to
accommodate not only organic anions but also neutral and
cationic molecules (Bossuyt et al., 1996; van Montfoort et al.,
2002). Octreotide appears also to be a transport substrate of
OATP1B1, although an accurate direct measurement of
[3H]octreotide uptake mediated by OATP1B1 was not possi-
ble. This was due to a high background signal measured in the
nontransfected CHO cells. This effect could not be abolished
nor reduced when the experiment was performed in ice,
suggesting that the signal was not due to a temperature-
dependent process, hence no endogenous carrier was likely to
account for such effect. It is possible that this background
signal resulted from a substantial membrane-bound compo-
nent due to lipid-protein electrostatic/hydrophobic interac-
tions (Beschiaschvili and Seelig, 1991). The transport rate of
[3H]octreotide uptake mediated by OATP1B1 was slow, even
under conditions that approach the influxKi value, suggesting
the octreotide is a better inhibitor than transport substrate of
OATP1B1. A marked difference in substrate and inhibitor
specificity is consistent with previous studies that have shown
other compounds to be strong inhibitors but poor substrates of
OATPs (Gui et al., 2008; de Graaf et al., 2011). From a kinetic
point of view, a compound that is capable of inhibiting the
transport of another substrate without itself being trans-
ported as well should be characterized by a relatively good
dissociation constant at the extracellular level (Ki/Kon) but
poor catalytic activity (Vmax/Kt) because an additional event
in the carrier cycle other than the extracellular binding
is sufficiently great compared with the Ki/Kon to impair
the entire cycle of the carrier (Eraly, 2008). Surprisingly
octreotide in the extracellular compartment was able to trans-
stimulate the efflux of intracellular [3H]E17bG (heteroex-
change) as efficiently as BSP, a known substrate of OATP1B1
(Kullak-Ublick et al., 2001). Because the trans-stimulation
usually enhances the cycling rate of the carrier without
affecting the binding, it can be assumed that the octreotide
transport itself was stimulated as well by the presence of
[3H]E17bG at the intracellular level (Goldman, 1971; Visentin
et al., 2012, 2015). This suggests that the outward-to-inward
translocation rate of the octreotide-OATP1B1 complex was
slow in a zero-trans condition (no substrate at the opposite side
of the plasma membrane) resulting in a slow uptake rate, but
presumably this was overcome in the infinite-trans condition
(another substrate in excess at the opposite side of the
membrane) when the cycling rate was maximized by the
TABLE 1.
Comparison of [3H]E17bG influx kinetic parameters in the presence or absence of nonlabeled octreotide
The inhibition constant (Ki) was determined from the formula: Kmapp = Km(1+[I]/Ki), where Kmapp and Km are the affinity
constants in the presence or absence of octreotide, respectively; [I] represents the extracellular concentration of octreotide.
Data are the mean 6 S.D. from four independent experiments.
Km Vmax Vmax/Km Ki
mM pmol/mg per minute mM
Control 4.4 6 1.2 107.4 6 8.9 23.9 6 9.7 —
+60 mM octreotide 8.8. 6 3.1* 107.0 6 9.9 11.4 6 5.7x 33.5 6 5.5
*P value 0.03, for the difference between Km values.xP value 0.01, for the difference between Vmax/Km values.
—: there is no inhibitor hence no Ki can be measured.
Fig. 5. Kinetic analysis of the inhibition of [3H]E17bG influx by
nonlabeled octreotide. Initial uptake of [3H]E17bG was assessed over
1 minute at pH 7.4 in OATP1B1-transfected CHO cells. Data were corrected
for uptake in CHO wild-type cells. (A) [3H]E17bG influx as a function of
the extracellular concentration of substrate and in the presence or absence
of nonlabeled octreotide at an extracellular concentration of 60 mM.
Results are the mean6 S.D. from four independent experiments. The line
is best-fit to the Michaelis-Menten equation [V = Vmax[S]/(Kt + [S])]. (B)
[3H]E17bG influx at the indicated extracellular concentrations (1 or 10 mM)
as a function of increasing extracellular concentrations of nonlabeled
octreotide. The line is derived by plotting 1/v against the concentration of
octreotide (inhibitor) (Dixon analysis) and represents the mean 6 S.D.
from three independent experiments.
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presence of substrates at both sides of the plasma membrane.
This was not the case for ICG, which was found to be a strong
OATP1B1 inhibitor, but no transport could be measured (de
Graaf et al., 2011). ICG at the extracellular compartment did
not stimulate but rather inhibited the efflux rate of intracel-
lular [3H]E17bG. The two possible explanations for this effect
are that: 1) ICG locked the carrier in the outward conforma-
tion or 2) the ICG-OATP1B1 complex did not dissociate at the
intracellular level (Koff), depleting the unloaded carrier frac-
tion accessible for [3H]E17bG export. These findings confirm
that the inhibition potency of a compound does not necessarily
imply that it is a transport substrate and suggest that this
trans-setting may represent a rapid approach to discriminate
between a substrate and a pure inhibitor without direct
assessment of the uptake of the radiolabeled or fluorescent
equivalent (Apiwattanakul et al., 1999; Bakhiya et al., 2003).
In fact, unlike in the cis-setting in which they confer similar
effects, substrate and inhibitor act differently in the trans-
setting, allowing rapid discrimination. This approach, to-
gether with the classic cis-inhibition assay, might allow the
rapid screening of potential substrates of the OATPs.
Octreotide showed a relatively strong inhibitory effect on
OATP1B1, whereas MRP2 was only weakly inhibited. This
finding is consistent with a previous study showing that in Eisai
hyperbilirubinemic rats (EHBR), that lack MRP2 expression,
the bile-to-liver concentration ratio of octreotide was comparable
to that in normal Sprague-Dawley rats, suggesting thatMRP2at
best plays a marginal role in the canalicular efflux of octreotide
in rodents (Yamada et al., 1996). Nevertheless, the same study
found that the overall hepatic excretion of octreotidewas reduced
in EHBR rats and that this was due solely to a reduced liver-to-
plasma concentration ratio. The hypothesis was that other
MRP2 substrates accumulated in the liver of EHBR rats and
were fluxed back into the blood stream where they competed
with octreotide at the sinusoidal level. Whether the sinusoidal
transport of octreotide in EHBR rats could be mediated by
OATPs was not demonstrated but is a reasonable assumption,
considering that OATPs andMRP2 share a variety of substrates
(Suzuki and Sugiyama, 1999). For instance, bilirubin glucuro-
nide, a substrate of OATPs and MRP2, is ∼50 times more
concentrated in the plasma ofEHBR thannormal rats (49 versus
1 mM) and may inhibit the uptake of octreotide into the
hepatocytes (Sathirakul et al., 1993; Yamada et al., 1997).
The current work establishes that octreotide may reduce
Na1-independent bile acid uptake mainly by inhibiting
OATP1B1-mediated transport. No interaction was found with
NTCP, the Na1-dependent bile acid transport system, in
accordancewith the observation that cationic compounds poorly
interfere with sodium-dependent taurocholate uptake into he-
patocytes (Hardison et al., 1984). This finding contrasts with
the previously reported marked reduction of [14C]octreotide
uptake in primary rat hepatocytes in the absence of Na1 or in
the presence of ouabain, which collapses the Na1 gradient
across the cell membrane (Terasaki et al., 1995). One possible
explanation for this discrepancy is that replacement of Na1 or
the collapse of its gradient alters themembrane potential and/or
pH-gradients and results in nonspecific effects. However in the
same study, the uptake of [14C]octreotide was more strongly
inhibited by BSP (IC50∼10mM) than by taurocholate (IC50∼100
mM), a pattern that suggests an OATP rather than an NTCP
inhibition (Hagenbuch and Meier, 1994; Shitara et al., 2009).
This study showed a clear inhibitory effect of octreotide on
the hepatic bilirubin carriers with a pronounced effect on
OATP1B1 transport activity. This finding could be relevant for
the prediction of potential drug-drug interactions. Octreotide,
when administered concomitantly, has been shown to increase
the bioavailability of the OATP1B1 substrate bromocriptine
by 40% (Flogstad et al., 1994; Lu et al., 2006). Additionally,
octreotide is rapidly cleared by the liver, suggesting an
extensive first-pass elimination if administered orally and
requiring much higher doses to achieve similar blood peak
concentrations (Cmax ∼ 5 nM) (Tuvia et al., 2012). At such
doses octreotide could reach the liver at much higher local
concentrations and could thereby modulate the clearance and
increase plasma levels of other OATP1B1 substrates.
Fig. 7. Analysis of [3H]E17bG efflux mediated by OATP1B1. OATP1B1- andWT-CHO cells were incubated for 30minutes with 10 mM [3H]E17bG. After
intracellular [3H]E17bGwas assessed, cells were washed at 0°C and then resuspended either in drug-free buffer or in buffer containing BSP (A), ICG (B),
or octreotide (C) at 37°C at the indicated concentrations. The decline in intracellular [3H]E17bG was monitored. The y axis is expressed as logarithmic
(base 10) scale. Values are the mean 6 S.D. from at least three independent experiments.
Fig. 6. Uptake of [3H]octreotide mediated by OATP1B1. Uptake of 10 mM
[3H]octreotide was assessed at the indicated time at pH 7.4 in OATP1B1-
transfected CHO cells and in WT-CHO cells. Results are the mean 6 S.D.
from three independent experiments.
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